<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599311</url>
  </required_header>
  <id_info>
    <org_study_id>PKUPH</org_study_id>
    <nct_id>NCT02599311</nct_id>
  </id_info>
  <brief_title>the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery</brief_title>
  <official_title>The Clinical Efficacy of Pelvic Organ Prolapse Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One thousand patients with stage＞2 POP are recruited. The patients are all received
      surgeries,such as transvaginal synthetic mesh surgery, the sacral fixation, tissue repair
      surgery and colpocleisis. The patients with POP who have not undergone surgery are excluded.
      Postoperatively, the investigators investigate the indications and clinical efficacy of
      pelvic organ prolapse surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperatively, the investigators analyze the patients' subjective and objective recurrent
      rates. The investigators compare the quality of life by filling out the preoperative and
      postoperative scoring questionnaires (PISQ 12, PFDI-20, PFIQ-7).The electrical physiological
      changes will be focused on. The investigators also use Overactive Bladder Symptom
      Score(OABss) to assess the lower urinary tract symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the objective recurrent rate</measure>
    <time_frame>one year after surgery</time_frame>
    <description>The objective recurrence means postoperative stage≥2 (POP-Q) in any compartment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of the lower urinary tract symptoms</measure>
    <time_frame>one year after surgery</time_frame>
    <description>We focus on lower urinary tract symptoms (LUTS), including frequent micturition, urgent urination, cough (or sneezing) leakage, dysuria, and urinary incontinence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the quality of life questionnaires</measure>
    <time_frame>one year after surgery</time_frame>
    <description>The QOL questionnaires include PFDI-20 and PFIQ-7.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>the efficacy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>transvaginal synthetic mesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the recurrence rate</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>transvaginal synthetic mesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the quality of life</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>transvaginal synthetic mesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the rate of the LUTS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>We use Tolterodine to improve patients' LUTS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transvaginal synthetic mesh</intervention_name>
    <description>transvaginal synthetic mesh</description>
    <arm_group_label>the efficacy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <description>Tolterodine tartrate can improve patients' LUTS.</description>
    <arm_group_label>the rate of the LUTS</arm_group_label>
    <other_name>Tolterodine tartrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients with stage＞2 POP are recruited.The patients are all received surgeries,
             which include transvaginal synthetic mesh surgery, the sacral fixation, tissue repair
             surgery and colpocleisis.

        Exclusion Criteria:

          -  The patients with POP who have not undergone surgery are excluded.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianliu Wang, professor</last_name>
    <role>Study Chair</role>
    <affiliation>department of Gynecology, Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Sun, professor</last_name>
    <phone>861088324354</phone>
    <email>zzucaotingting@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tingting Cao, resident</last_name>
      <phone>861088324354</phone>
      <email>sxlctt2015@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>May 21, 2017</last_update_submitted>
  <last_update_submitted_qc>May 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pelvic organ prolapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

